In this powerful and urgent episode, Dr. Joseph Piacentile — physician, attorney, and longtime whistleblower advocate — sits down with Dr. Robert E. Lee, a distinguished vascular surgeon and former FDA medical officer. Together, they reveal shocking details about the FDA's December 2024 approval of the Symvess graft, a vascular device developed by Humacyte Corporation, now cleared for use in trauma surgery — including on U.S. soldiers.

Dr. Lee, who spent nearly a decade reviewing vascular devices for the FDA, exposes how internal concerns from at least four FDA-affiliated vascular surgeons were ignored, and how the product was approved despite catastrophic failures, including life-threatening hemorrhages and patient deaths. He details the lack of transparency, the suppression of internal dissent, and how the FDA bypassed the standard public hearing process.

This conversation is a whistleblower’s warning to the new FDA Commissioner, Dr. Marty Makary, and the Secretary of Defense, Mr. Pete Hegseth, urging immediate action before this unproven and dangerous device is deployed widely across the military and civilian hospitals.

📌 Topics Covered:

-What is the Symvess graft and how does it differ from traditional grafts?

-Why Humacyte’s clinical trial data raises red flags

-The FDA's deviation from its own review protocols

-Why battlefield use of Symvess could be deadly

-How a panel hearing was bypassed

-Dr. Lee’s call for congressional and public oversight

⚠️ This episode is a call to action. It is about accountability, transparency, and protecting the lives of soldiers and civilians alike.

🎧 Follow and stay informed on the follow-up investigations and developments.

#Whistleblower #FDA #Humacyte #CIMVAS #MedicalDevices #VascularSurgery #MilitaryMedicine #PatientSafety #DrJosephPiacentile #DrRobertELee #PublicHealth #Podcast